Lilly rides Mounjaro, Zepbound to better
Rapidly climbing sales of the new obesity drug Zepbound and its counterpart for diabetes, Mounjaro, pushed Eli Lilly to a better-than-expected first-quarter profit.
The drugmaker also hiked its sales and earnings forecast for 2024 beyond Wall Street’s expectations even as it hustles to boost manufacturing and catch up to surging demand for the drugs.
Lilly said it was still dealing with supply issues that also hampered the company in the fourth quarter. Company officials expect that to persist through this year, but they emphasized Tuesday that help was on the way.
They expect significant manufacturing increases to occur, starting in the back half of the year.
CEO David Ricks told analysts Tuesday that Lilly was undergoing “the most ambitious expansion plan in our company’s history.”
Indianapolis-based Eli Lilly and Co. recorded $517 million in sales from Zepbound, which received approval from U.S. regulators last November. Total Mounjaro sales more than tripled to $1.81 billion from $568 million in last year’s quarter.
Related articles
Encino out of Kentucky Derby, Epic Ride joins the 20
LOUISVILLE, Ky. (AP) — Encino won’t run in the Kentucky Derby this weekend, trainer Brad Cox said Tu2024-05-01Farms a hive of activity across China
A farmer operates a drone in a field in Qingshan Town of Chongyang County, central China's Hubei Pro2024-05-01Highlights of Beijing 2022 Paralymic Torch Relay and Flame Lighting Ceremony
Staff members display the flame during the Beijing 2022 Paralymic Torch Relay and Flame Lighting Cer2024-05-01Xi Encourages Young Researchers to Make Breakthroughs in Cutting
Contact Us HomeNewsHighlightACWF NewsSocietyWom2024-05-01Ahead of the Paris Olympics, police clear a migrant camp near City Hall
PARIS (AP) — French police evicted migrants from a makeshift tent-camp next to Paris City Hall early2024-05-01Xi Sends Congratulatory Letter to Forum on Civilization and Sinology
Contact Us HomeNewsHighlightACWF NewsSocietyWom2024-05-01
atest comment